Clinical Trials Directory

Trials / Completed

CompletedNCT00671411

Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast

Evaluation of Renal Masses Using Ultrasound Intravenous Microbubble Contrast

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Memorial Sloan Kettering Cancer Center · Academic / Other
Sex
All
Age
21 Years – 99 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the blood flow in kidney masses by using ultrasound microbubble contrast material, and to see if results from ultrasound contrast studies can predict if a kidney mass is benign or malignant. Patterns of blood flow in the kidney mass will be examined to see if: 1. benign kidney masses can be distinguished from kidney cancers and 2. if slow growing, lower risk cancers have different blood flow compared to clear cell cancer which is the most common type of kidney cancer.

Conditions

Interventions

TypeNameDescription
DRUGUltrasound with intravenous microbubble contrast injectionIntravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings \& Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 \& 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of "flash" bubble destruction may be optionally triggered using manufacturer's preset settings \& energy w/i FDA guidelines. This will only be performed while imaging the kidney.

Timeline

Start date
2008-03-01
Primary completion
2011-11-01
Completion
2011-11-01
First posted
2008-05-05
Last updated
2015-12-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00671411. Inclusion in this directory is not an endorsement.